Sugi Predict

Sugi Predict / Compounds / SCHEMBL2073401

SCHEMBL2073401

SCHEMBL2073401

Cln1[c]cc2ccccc21

nearest known ligand 0.32

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ CDK4 P11802 3/20 0.32
▸ CCND1 P24385 3/20 0.32
▸ CYP2A6 P11509 1/20 0.32
▸ ALOX12 P18054 1/20 0.32
▸ BIRC5 O15392 1/20 0.31
▸ RECQL P46063 1/20 0.31
▸ CA12 O43570 2/20 0.30
▸ CA9 Q16790 2/20 0.30
▸ BRD4 O60885 1/20 0.30
▸ BRPF1 P55201 1/20 0.30
▸ KAT2B Q92831 1/20 0.30
▸ BRD9 Q9H8M2 1/20 0.30
▸ ALDH1A1 P00352 1/20 0.30
▸ MAPT P10636 1/20 0.30
▸ SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL570353 0.71 CDK4 (0.32) CDK4CCND1CYP2A6ALOX12CA12
SCHEMBL137023 0.71 CA12 (0.39) CDK4CCND1CYP2A6ALOX12RECQL
SCHEMBL3849038 0.71 CA12 (0.34) CDK4CCND1CYP2A6ALOX12CA12
SCHEMBL127255 0.71 DAO (0.35) CDK4CCND1CYP2A6ALOX12CA12
SCHEMBL650735 0.71 NOS2 (0.34) CDK4CCND1CYP2A6ALOX12BIRC5
SCHEMBL2073630 0.71 CDK4 (0.32) CDK4CCND1CYP2A6ALOX12CA12
SCHEMBL15271285 0.71 RECQL (0.35) CDK4CCND1RECQL
SCHEMBL1642678 0.70 DAO (0.39) ALDH1A1SMN1; SMN2
SCHEMBL5788693 0.69 NOTUM (0.47) CA12CA9BRD4BRPF1KAT2B
SCHEMBL1201646 0.69 RECQL (0.44) RECQLALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118241315-A Chlorine-containing indolyl nonlinear optical crystal, preparation method and application thereof 天津理工大学 2024-06-25 — — CN claimed
EP-1670739-A4 CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2007-08-08 — — EP claimed
EP-1670739-A2 CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS Bristol-Myers Squibb Company (US) 2006-06-21 — — EP claimed
US-20050085511-A1 Cyclic diamines and derivatives as factor Xa inhibitors BRISTOL-MYERS SQUIBB COMPANY 2005-04-21 — — US claimed
WO-2005032490-A2 CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2005-04-14 — — WO claimed
US-6333339-B1 CENTRAL SYSTEM DISORDERS, SCHIZOPHRENIA AND COGNITION ACTIVATORS MERCK PATENT GELLSCHAFT MIT BESCHRANKTER (DE) 2001-12-25 — — US claimed
CN-118241315-A Chlorine-containing indolyl nonlinear optical crystal, preparation method and application thereof 天津理工大学 2024-06-25 — — CN disclosed
CN-118241315-A Chlorine-containing indolyl nonlinear optical crystal, preparation method and application thereof 天津理工大学 2024-06-25 — — CN disclosed
CN-118234723-A Pesticidally active heterocyclic derivatives with sulfoximine containing substituents 先正达农作物保护股份公司 2024-06-21 — — CN disclosed
CN-117561252-A 2- [3- [1[ (quinazolin-4-yl) amino ] ethyl ] pyrazin-2-yl ] thiazole-5-carbonitrile derivatives and similar compounds as pesticides 先正达农作物保护股份公司 2024-02-13 — — CN disclosed
CN-117561250-A Heterocyclic compound and harmful arthropod control composition containing same 住友化学株式会社 2024-02-13 — — CN disclosed
CN-117545356-A Heterocyclic compound and method for controlling drug-resistant harmful arthropods by using composition containing same 住友化学株式会社 2024-02-09 — — CN disclosed
CN-117529477-A Pesticidally active diazine-amide compounds 先正达农作物保护股份公司 2024-02-06 — — CN disclosed
EP-1341766-B1 IMIDAZOLONE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES HOFFMANN LA ROCHE (CH) 2005-10-26 — — EP disclosed
US-20050085511-A1 Cyclic diamines and derivatives as factor Xa inhibitors BRISTOL-MYERS SQUIBB COMPANY 2005-04-21 — — US disclosed
WO-2005032490-A2 CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2005-04-14 — — WO disclosed
EP-1341766-A1 IMIDAZOLONE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES F. HOFFMANN-LA ROCHE AG (CH) 2003-09-10 — — EP disclosed
US-6518293-B2 Inhibitors of the human immunodeficiency virus reverse transcriptase enzyme which is involved in viral replication. HOFFMANN-LA ROCHE INC. 2003-02-11 — — US disclosed
US-20020107272-A1 Anti-HIV imidazolone derivatives F. HOFFMANN-LA ROCHE AG (CH) 2002-08-08 — — US disclosed
WO-2002042279-A1 IMIDAZOLONE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES F. HOFFMANN-LA ROCHE AG (CH) 2002-05-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107272-A1 Anti-HIV imidazolone derivatives EIF2AK2, IMPDH1, POLR2E CDK4 80/4885CCND1 622/4885CYP2A6 1283/4885
US-20050085511-A1 Cyclic diamines and derivatives as factor Xa inhibitors TFPI, SERPINC1, F12 CDK4 4613/4885CCND1 3991/4885CYP2A6 3604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.